Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Non-Small Cell Lung Cancer (NSCLC) · Colorectal Cancer · Pancreatic Ductal Adenocarcinoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 534 (planned)
- Started
- Nov 14, 2023
- Main results expected
- Dec 2028
- Fully finished
- Jun 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of patients with adverse events (AEs) in Phase 1b
Measured over: Up to approximately 3 years
Changes in vital signs in Phase 1b
Measured over: Up to approximately 3 years
Changes in clinical laboratory test values in Phase 1b
Measured over: Up to approximately 3 years
Dose Limiting Toxicities in Phase 1b
Measured over: 21 days
Changes in ECGs in Phase 1b
Measured over: Up to approximately 3 years
Overall Response Rate (ORR) in Phase 2
Measured over: Up to approximately 3 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06128551 · record last updated 2026-09-22 · checked 2026-11-09 15:47 UTC